Max Rosett

CFO Max Rosett sold 60,000 IMNM shares ($1.1M) under 10b5-1 plan; stock down 33.0% from 52-week high.

Max Rosett, Chief Financial Officer of Immunome Inc., sold 60,000 shares at $18.23 on 2026-06-15 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-26, reducing his non-derivative holdings to 54,037 shares from 114,037 shares. The sale occurs within a deeply challenged fundamental context: the company reported $0.00 revenue in its latest quarter, a net loss of $-53,839,000.00, and an annual revenue decline of -23.2%. The stock has declined 33.0% from its 52-week high and is down 6.9% over the past 30 days. The transaction is scheduled rather than discretionary, so timing attributions do not apply; however, his prior two same-ticker sales at IMNM on 2026-04-02 (achieving 30-day returns of 3.7% and 1.1%) provide no clear signal of accurate market-timing ability at this ticker. The combination of severe revenue contraction, substantial operating losses, and continued insider stock disposals warrants attention to the company's path to profitability.

CFO Rosett Max sold 65,000 shares ($1.4M) via scheduled 10b5-1 plan; retains 54,037 shares post-sale

Rosett Max, Chief Financial Officer of Immunome Inc., executed 2 separate sales totaling 65,000 shares for $1,424,916.08 on 2026-04-02 at a blended average price of $21.92. This represents a 54.6% reduction in his pre-transaction holdings from 119,037 shares to 54,037 shares post-transaction. The sale was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-12-26, indicating a scheduled disposition rather than a discretionary decision. The magnitude of the reduction—from 119K to 54K shares—reflects a material liquidity event, though the scheduled nature of the plan removes timing-based inference about market outlook.